Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

A key decision by the bankruptcy judge could help with protecting consumer data, write Diane Lourdes Dick and Anya Prince.

Bankrupt genetic testing company 23andMe is looking to sell its assets — most notably its customers' DNA data — for more than ...

(Reuters) -Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data ...

Bankrupt genetic analysis company 23andMe will hold a second auction for its cache of DNA data with an opening bid of $305 ...

The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the ...

Me will hold a second auction for its DNA data with an opening bid of $305 million from former CEO Anne Wojcicki. Here's all ...

Once a Silicon Valley pioneer in consumer genetic testing, 23andMe is now at the center of a high-stakes legal and financial ...

After a brief court dispute, 23andMe and all its assets are up for auction once again. The second time around, former CEO Amy ...